COMPASS PATHWAYS PLC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
COMPASS PATHWAYS PLC (CMPS) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding of $10.97 million as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding · last filed 2026-03-24
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $10.97M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $6.01M.
- 2024-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $15.29M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding $14.07M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding |
|---|---|
| 2025-12-31 | $10.97M 10-K · filed 2026-03-24 |
| 2024-12-31 | $6.01M 10-K · filed 2026-03-24 |
| 2024-03-31 | $15.29M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $14.07M 10-K · filed 2025-02-27 |
| 2023-09-30 | $11.41M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $13.55M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $17.65M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $13.01M 10-K · filed 2024-02-29 |
| 2022-09-30 | $17.85M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $18.28M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $24.25M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $51.16M 10-K · filed 2023-02-28 |
| 2020-12-31 | $186.43M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |